Navigation Links
Optimer Pharmaceuticals Reports Fourth Quarter and Full Year 2010 Financial Results
Date:3/10/2011

ed clinical cure vs. 90.6% for Vancocin®.  Importantly, fidaxomicin also showed significantly lower recurrence rates (p=0.002) and higher global cure rates (p<0.001) compared to Vancocin.  

Scheduled Conference CallThe Company will host both a conference call and webcast to discuss the fourth quarter and full year 2010 financial results and to provide a corporate update today, Thursday, March 10, 2011 at 4:30 p.m. Eastern time (1:30 p.m. Pacific time).

The conference call may be accessed by dialing (877) 280-7280 for domestic callers and (678) 825-8232 for international callers.  Please specify to the operator that you would like to join the "Optimer Earnings Call." The conference call will be webcast live under the Investors section of Optimer's website at www.optimerpharma.com, where it will be archived for 30 days following the call.About Optimer PharmaceuticalsOptimer Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing hospital specialty products to treat serious infections and address unmet medical needs. Optimer has two anti-infective product candidates in development, fidaxomicin and Pruvel™ (prulifloxacin). Fidaxomicin is a narrow spectrum antibiotic being developed for the treatment of Clostridium difficile infection (CDI). The FDA granted the Company's request for six-month Priority Review of fidaxomicin, and has assigned a Prescription Drug User Fee Act (PDUFA) goal date of May 30, 2011. The Company also filed a MAA with the European Medicines Agency (EMA) for fidaxomicin. Pruvel™ is a prodrug in the fluoroquinolone class of antibiotics being developed as a treatment for infectious diarrhea. Additional information can be found at http://www.optimerpharma.com.

Forward-looking StatementsStatements included in this press release that are not a
'/>"/>

SOURCE Optimer Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Optimer Pharmaceuticals Receives Production Patent for Lead Product Candidate Fidaxomicin
2. Optimer Pharmaceuticals Presents Results From Fidaxomicin Phase 3 Study for the Treatment of Clostridium difficile Infection
3. Data From Optimers Second Phase 3 Study of Prulifloxacin Presented at Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)
4. Optimer Announces Presentation of Additional Data From Fidaxomicin Phase 3 Study for the Treatment of Clostridium Difficile Infection (CDI)
5. Optimer Pharmaceuticals to Present at the 21st Annual Piper Jaffray Health Care Conference
6. Optimer Pharmaceuticals to Present at the 28th Annual J.P. Morgan Healthcare Conference
7. Optimer Pharmaceuticals Fidaxomicin Marketing Authorization Application Accepted for Review by European Medicines Agency
8. Optimer Pharmaceuticals to Present at September 2010 Investor Conferences
9. Optimer Pharmaceuticals Announces Presentations of Additional Fidaxomicin Phase 3 Data at Upcoming ICAAC Annual Meeting
10. Optimer Pharmaceuticals Announces Combined Data From Fidaxomicin Phase 3 Trials for the Treatment of Clostridium difficile Infection (CDI) Presented at IDSA
11. Optimer Pharmaceuticals to Host Investor and Analyst Event on November 18
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... 22, 2014 Apnea Sciences ( www.apneasciences.com ) ... Aliso Viejo , California.  Jimmy ... tremendous growth and worldwide expansion, a new facility with ... the anti snore cure have exceeded our expectations and ... are now in 23 countries and will be increasing ...
(Date:12/22/2014)... MEMPHIS, Tenn. , Dec. 22, 2014   ... only automated, no-touch UV disinfection robot, announced today that ... GSA Schedule contract through November 2019.   ... to rapidly engage all levels of government purchasers, including ... facilities, as well as Homeland Security contacts purchasing solutions ...
(Date:12/22/2014)...  ConvaTec, a privately-held medical products and technologies company, ... Chief Executive Officer of the company, effective December 22, ... .  "The Board of Directors of ConvaTec thanks Mr. ... past three years," said Magnus Lundberg , the ... that the company is well positioned for the future."  ...
Breaking Medicine Technology:TRU-D SmartUVC LLC Awarded General Services Administration Contract to Expand Government Customer Base 2ConvaTec Names Paul Moraviec Interim CEO Effective December 22, 2014 2
... SAN DIEGO, Oct. 27 Orexigen® Therapeutics, Inc. (Nasdaq: ... (ITT) analyses from the COR-I and COR-II Phase 3 trials ... stage Orexigen candidates for the treatment of obesity. These ... findings from a panel discussion on Saturday where the Company ...
... from a phase II study demonstrated that oral ... frequency of bowel movements in patients with opioid-induced ... an oral peripherally-acting opioid antagonist, is an investigational ... of opioid-induced constipation. , (Logo: ...
Cached Medicine Technology:Orexigen(R) Therapeutics Releases New Efficacy Data for Contrave(R) in Late Breaker Presentations at the 27th Annual Scientific Meeting of The Obesity Society 2Orexigen(R) Therapeutics Releases New Efficacy Data for Contrave(R) in Late Breaker Presentations at the 27th Annual Scientific Meeting of The Obesity Society 3Orexigen(R) Therapeutics Releases New Efficacy Data for Contrave(R) in Late Breaker Presentations at the 27th Annual Scientific Meeting of The Obesity Society 4Orexigen(R) Therapeutics Releases New Efficacy Data for Contrave(R) in Late Breaker Presentations at the 27th Annual Scientific Meeting of The Obesity Society 5Orexigen(R) Therapeutics Releases New Efficacy Data for Contrave(R) in Late Breaker Presentations at the 27th Annual Scientific Meeting of The Obesity Society 6Phase 2 Data From Oral NKTR-118 Presented at American College of Gastroenterology in San Diego 2Phase 2 Data From Oral NKTR-118 Presented at American College of Gastroenterology in San Diego 3Phase 2 Data From Oral NKTR-118 Presented at American College of Gastroenterology in San Diego 4
(Date:12/24/2014)... 2014 Dr. Svetlana Gomer, MGS Tewksbury ... nation gathered with US Marines on November 14, 2014 ... for the Toys for Tots Literacy Program. This ... new books and audio books for the Toys for ... this Christmas. It represents another major strike in the ...
(Date:12/24/2014)... The report offers details on the global sports ... such as the key trends, the orthopedic market, the ... U.S. sports medicine, the impact of the global economy ... by the market. , Browse report with table of ... provides an overview of the global as well as ...
(Date:12/24/2014)... GA (PRWEB) December 24, 2014 Verde Pointe ... comical than ever. "Last years homemade Christmas sweater lit ... uglier. The 2014 winner is Tandy Wilson for the ... ugly sweater enthusiast," says Kirk Kimmerling DDS. "She took pictures ... angels on the sweater." , "Every year I ...
(Date:12/24/2014)... FL (PRWEB) December 24, 2014 Dental ... solution for a tooth replacement. They offer the strongest ... several advantages over other forms of tooth replacement. They ... rely on the adjacent teeth for support, and they ... people have been told that they are not suitable ...
(Date:12/24/2014)... Attorneys handling talcum powder cancer lawsuits at ... website, the Talcum Powder Ovarian Cancer Center. ... action lawsuits and ovarian cancer claims. These baby powder ... at their website, which serves as a national public ... are not the same as class action lawsuits,” explains ...
Breaking Medicine News(10 mins):Health News:Dr. Svetlana Gomer, MGS Tewksbury Dental and Other Dentists Working With the U.S. Marines Strike Again In the Battle Against Illiteracy 2Health News:Dr. Svetlana Gomer, MGS Tewksbury Dental and Other Dentists Working With the U.S. Marines Strike Again In the Battle Against Illiteracy 3Health News:Sports Medicine Market Report 2014: Global Industry Analysis, Share, Size, Trends, Growth and Forecast report 2Health News:Verde Pointe Dental Associates Announces the 2014 Ugly Sweater Holiday Contest Winner 2Health News:Innovative Dental Implant Procedure to Gain Momentum in the New Year 2Health News:Talcum Powder Attorneys Explain Class Action Lawsuits 2Health News:Talcum Powder Attorneys Explain Class Action Lawsuits 3Health News:Talcum Powder Attorneys Explain Class Action Lawsuits 4
... (HealthDay News) -- Some HIV patients experience memory loss ... suggests that the reason why is because the virus ... of supporting brain cells called astrocytes. The blood-brain ... the brain from harmful chemicals and toxins. In healthy ...
... teaming up to offer one of the nation,s most ... Led by the University of Maryland and the ... will target the so-called short-haul "drayage" fleet that shuttles ... The effort seeks to double the impact of ...
... News) -- Cancer patients taking the drugs sunitinib and ... the drugs don,t cause as much damage to the ... small study included 40 volunteers in the Netherlands, including ... were treated with sorafenib. Seven patients with metastatic renal ...
... Kathleen Doheny HealthDay Reporter , TUESDAY, June 28 ... more than most experts have long believed, according to a ... follow-up of nearly three decades -- the longest ever -- ... clearer as the decades roll on. In fact, most ...
... 2011 Earl L. Smith III, O.D., dean of the ... received an award for his work in slowing the progression ... the endowed Greeman-Petty Professor chair, accepted the Donald Korb Award ... lens and cornea section of the American Optometric Association (AOA). ...
... & Science University have discovered a naturally occurring disease in ... a discovery that could have a major impact on ... The disease that the researchers discovered in monkeys at OHSU,s ... virus that could give significant clues into how multiple sclerosis ...
Cached Medicine News:Health News:Research Sheds Light on Cause of Brain Deficits in HIV Patients 2Health News:Mid-Atlantic states' unique plan to replace region's dirtiest trucks 2Health News:Mid-Atlantic states' unique plan to replace region's dirtiest trucks 3Health News:Certain Cancer Drugs Don't Interfere With Flu Vaccine: Study 2Health News:Longest Trial Ever Confirms Mammograms' Benefits 2Health News:Longest Trial Ever Confirms Mammograms' Benefits 3Health News:Work to slow progression of nearsightedness in children wins award 2Health News:Researchers at Oregon Health & Science University discover MS-like disease in monkeys 2
Polyester ribbons (3) impregnated with different OD values of conjugated Protein G...
Colloidal Gold Sol, 80 nm - 12 - 15 OD, 1 ml, Gold Sol Nanoparticles - not boiled, not centrifuged...
Colloidal Gold Sol, 20 nm - 12 - 15 OD, 1 ml, Gold Sol Nanoparticles - not boiled, not centrifuged...
... Pachymeter [i.e., PalmScan P2000] device is ... which incorporates A-mode pulsed-echo ultrasound,technology, and ... measure the corneal thickness (CT) and,epithelium ... P2000 includes two software user,interfaces; a ...
Medicine Products: